Bol, J.M. van der

patient irinotecan cancer pharmacokinetic dosing clearance study group neutropenia effect treatment course toxicity -38 sn -38 variability metabolite interindividual variability docetaxel exposure strategy smoking analysis bsa-based value creatinine clearance sn -38g interindividual mathijssen polymorphism omeprazole verweij j smoker creatinine methimazole result grade level sparreboom cyp 3a function verweij bsa-based dosing oncol table van der bol concentration downloaded pharmacol anticancer cancer patients bsa-based dosing group genotype ugt 1a jong fa population interindividual pharmacokinetic variability mathijssen rh factor incidence irinotecan treatment parameter nonsmokers pk-guided body surface area january oncology decrease relationship research plasma addition article toxicitie metabolism nadir american association bruijn p anticancer drugs